Aegerion Pharma (AEGR) Tops Q3 EPS by 8c

Aegerion Pharma (NASDAQ: AEGR) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $59.72 million.

Aegerion Pharma sees FY2015 revenue of $230-245 million, versus the consensus of $239.1 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Hermès can regain momentum despite China weakness, Jefferies says
• C.H. Robinson acquires DeSpir Logistics for $75 million